{"id":198303,"date":"2024-10-19T12:37:26","date_gmt":"2024-10-19T12:37:26","guid":{"rendered":"https:\/\/pdfstandards.shop\/product\/uncategorized\/aami-11137-2-2013-ra-2019\/"},"modified":"2024-10-25T05:10:32","modified_gmt":"2024-10-25T05:10:32","slug":"aami-11137-2-2013-ra-2019","status":"publish","type":"product","link":"https:\/\/pdfstandards.shop\/product\/publishers\/aami\/aami-11137-2-2013-ra-2019\/","title":{"rendered":"AAMI 11137 2 2013 RA 2019"},"content":{"rendered":"
Describes methods that can be used to determine the minimum dose necessary to achieve the specified requirement for sterility, including methods to substantiate 25 kGy as the sterilization dose.<\/p>\n
PDF Pages<\/th>\n | PDF Title<\/th>\n<\/tr>\n | ||||||
---|---|---|---|---|---|---|---|
1<\/td>\n | ANSI\/AAMI\/ISO 11137-2:2013\/(R)2019, Sterilization of health care products \u2014 Radiation \u2014Part 2: Establishing the sterilization dose <\/td>\n<\/tr>\n | ||||||
3<\/td>\n | Title page <\/td>\n<\/tr>\n | ||||||
4<\/td>\n | AAMI Standard Copyright information \n <\/td>\n<\/tr>\n | ||||||
5<\/td>\n | Contents <\/td>\n<\/tr>\n | ||||||
7<\/td>\n | Glossary of equivalent standards <\/td>\n<\/tr>\n | ||||||
8<\/td>\n | Committee representation <\/td>\n<\/tr>\n | ||||||
11<\/td>\n | Background of ANSI\/AAMI adoption of ISO 11137-2:2013 <\/td>\n<\/tr>\n | ||||||
12<\/td>\n | Foreword <\/td>\n<\/tr>\n | ||||||
13<\/td>\n | Introduction <\/td>\n<\/tr>\n | ||||||
15<\/td>\n | 1 Scope 2 Normative references 3 Terms, definitions and abbreviated terms 3.1 Terms and definitions <\/td>\n<\/tr>\n | ||||||
17<\/td>\n | 3.2 Abbreviated terms <\/td>\n<\/tr>\n | ||||||
18<\/td>\n | 4 Definition and maintenance of product families for dose setting, dose substantiation and sterilization dose auditing 4.1 General <\/td>\n<\/tr>\n | ||||||
19<\/td>\n | 4.2 Defining product families <\/td>\n<\/tr>\n | ||||||
20<\/td>\n | 4.3 Designation of product to represent a product family for performance of a verification dose experiment or sterilization dose audit 4.3.1 Product to represent a product family 4.3.2 Master product 4.3.3 Equivalent product <\/td>\n<\/tr>\n | ||||||
21<\/td>\n | 4.3.4 Simulated product 4.4 Maintaining product families 4.4.1 Periodic review 4.4.2 Modification to product and\/or manufacturing process 4.4.3 Records 4.5 Effect of failure of establishment of sterilization dose or of a sterilization dose audit on a product family <\/td>\n<\/tr>\n | ||||||
22<\/td>\n | 5 Selection and testing of product for establishing the sterilization dose 5.1 Nature of product <\/td>\n<\/tr>\n | ||||||
23<\/td>\n | 5.2 Sample item portion (SIP) <\/td>\n<\/tr>\n | ||||||
24<\/td>\n | 5.3 Manner of sampling 5.4 Microbiological testing 5.5 Irradiation <\/td>\n<\/tr>\n | ||||||
25<\/td>\n | 6 Methods of dose establishment 7 Method 1: dose setting using bioburden information 7.1 Rationale <\/td>\n<\/tr>\n | ||||||
26<\/td>\n | 7.2 Procedure for Method 1 for product with an average bioburden greater than or equal to 1.0 for multiple production batches 7.2.1 General <\/td>\n<\/tr>\n | ||||||
27<\/td>\n | 7.2.2 Stage 1: Select SAL and obtain samples of product 7.2.3 Stage 2: Determine average bioburden 7.2.4 Stage 3: Obtain verification dose <\/td>\n<\/tr>\n | ||||||
28<\/td>\n | 7.2.5 Stage 4: Perform verification dose experiment 7.2.6 Stage 5: Interpretation of results 7.2.7 Stage 6: Establish sterilization dose <\/td>\n<\/tr>\n | ||||||
32<\/td>\n | 7.3 Procedure for Method 1 for product with an average bioburden greater than or equal to 1.0 for a single production batch 7.3.1 Rationale 7.3.2 General 7.3.3 Stage 1: Select SAL and obtain samples of product <\/td>\n<\/tr>\n | ||||||
33<\/td>\n | 7.3.4 Stage 2: Determine average bioburden 7.3.5 Stage 3: Obtain verification dose 7.3.6 Stage 4: Perform verification dose experiment <\/td>\n<\/tr>\n | ||||||
34<\/td>\n | 7.3.7 Stage 5: Interpretation of results 7.3.8 Stage 6: Establish sterilization dose 7.4 Procedure for Method 1 for product with an average bioburden in the range 0.1 to 0.9 for multiple or single production batches <\/td>\n<\/tr>\n | ||||||
35<\/td>\n | 8 Method 2: Dose setting using fraction positive information from incremental dosing to determine an extrapolation factor 8.1 Rationale <\/td>\n<\/tr>\n | ||||||
36<\/td>\n | 8.2 Procedure for Method 2A 8.2.1 General 8.2.2 Stage 1: Select SAL and obtain samples of product 8.2.3 Stage 2: Perform incremental dose experiment 8.2.3.1 General <\/td>\n<\/tr>\n | ||||||
37<\/td>\n | 8.2.3.2 A and FFP 8.2.3.3 D* <\/td>\n<\/tr>\n | ||||||
38<\/td>\n | 8.2.3.4 CD* batch 8.2.4 Stage 3: Perform verification dose experiment <\/td>\n<\/tr>\n | ||||||
39<\/td>\n | 8.2.5 Stage 4: Interpretation of results 8.2.6 Stage 5: Establish sterilization dose <\/td>\n<\/tr>\n | ||||||
40<\/td>\n | 8.3 Procedure for Method 2B 8.3.1 General 8.3.2 Stage 1: Select SAL and obtain samples of product 8.3.3 Stage 2: Perform incremental dose experiment 8.3.3.1 General <\/td>\n<\/tr>\n | ||||||
41<\/td>\n | 8.3.3.2 A and FFP 8.3.3.3 D* <\/td>\n<\/tr>\n | ||||||
42<\/td>\n | 8.3.3.4 CD* batch 8.3.4 Stage 3: Perform verification dose experiment <\/td>\n<\/tr>\n | ||||||
43<\/td>\n | 8.3.5 Stage 4: Interpretation of results 8.3.6 Stage 5: Establish sterilization dose 9 Method VDmax \u2014 Substantiation of 25 kGy or 15 kGy as the sterilization dose 9.1 Rationale <\/td>\n<\/tr>\n | ||||||
44<\/td>\n | 9.2 Procedure for Method VDmax25 for multiple production batches 9.2.1 General <\/td>\n<\/tr>\n | ||||||
45<\/td>\n | 9.2.2 Stage 1: Obtain samples of product 9.2.3 Stage 2: Determine average bioburden 9.2.4 Stage 3: Obtain VDmax25 <\/td>\n<\/tr>\n | ||||||
47<\/td>\n | 9.2.5 Stage 4: Perform verification dose experiment 9.2.6 Stage 5: Interpretation of results <\/td>\n<\/tr>\n | ||||||
48<\/td>\n | 9.2.7 Confirmatory verification dose experiment 9.2.7.1 General 9.2.7.2 Stage 1: Obtain samples of product 9.2.7.3 Stage 2: Perform confirmatory verification dose experiment 9.2.7.4 Stage 3: Interpretation of results <\/td>\n<\/tr>\n | ||||||
49<\/td>\n | 9.3 Procedure for Method VDmax25 for a single production batch 9.3.1 Rationale 9.3.2 General 9.3.3 Stage 1: Obtain samples of product 9.3.4 Stage 2: Determine average bioburden 9.3.5 Stage 3: Obtain VDmax25 <\/td>\n<\/tr>\n | ||||||
50<\/td>\n | 9.3.6 Stage 4: Perform verification dose experiment 9.3.7 Stage 5: Interpretation of results <\/td>\n<\/tr>\n | ||||||
51<\/td>\n | 9.3.8 Confirmatory verification dose experiment 9.3.8.1 General 9.3.8.2 Stage 1: Obtain samples of product 9.3.8.3 Stage 2: Perform confirmatory verification dose experiment 9.3.8.4 Stage 3: Interpretation of results <\/td>\n<\/tr>\n | ||||||
52<\/td>\n | 9.4 Procedure for Method VDmax15 for multiple production batches 9.4.1 General 9.4.2 Stage 1: Obtain samples of product 9.4.3 Stage 2: Determine average bioburden 9.4.4 Stage 3: Obtain VDmax15 <\/td>\n<\/tr>\n | ||||||
53<\/td>\n | 9.4.5 Stage 4: Perform verification dose experiment <\/td>\n<\/tr>\n | ||||||
54<\/td>\n | 9.4.6 Stage 5: Interpretation of results 9.4.7 Confirmatory verification dose experiment 9.4.7.1 General 9.4.7.2 Stage 1: Obtain samples of product 9.4.7.3 Stage 2: Perform confirmatory verification dose experiment <\/td>\n<\/tr>\n | ||||||
55<\/td>\n | 9.4.7.4 Stage 3: Interpretation of results 9.5 Procedure for Method VDmax15 for a single production batch 9.5.1 Rationale 9.5.2 General 9.5.3 Stage 1: Obtain samples of product 9.5.4 Stage 2: Determine average bioburden <\/td>\n<\/tr>\n | ||||||
56<\/td>\n | 9.5.5 Stage 3: Obtain VDmax15 9.5.6 Stage 4: Perform verification dose experiment 9.5.7 Stage 5: Interpretation of results <\/td>\n<\/tr>\n | ||||||
57<\/td>\n | 9.5.8 Confirmatory verification dose experiment 9.5.8.1 General 9.5.8.2 Stage 1: Obtain samples of product 9.5.8.3 Stage 2: Perform confirmatory verification dose experiment 9.5.8.4 Stage 3: Interpretation of results <\/td>\n<\/tr>\n | ||||||
58<\/td>\n | 10 Sterilization dose audit 10.1 Purpose and frequency 10.2 Procedure for auditing a sterilization dose established using Method 1, Method 2A or Method 2B 10.2.1 General 10.2.2 Stage 1: Obtain samples of product 10.2.3 Stage 2: Determine average bioburden <\/td>\n<\/tr>\n | ||||||
59<\/td>\n | 10.2.4 Stage 3: Perform verification dose experiment 10.2.5 Stage 4: Interpretation of results <\/td>\n<\/tr>\n | ||||||
60<\/td>\n | 10.2.6 Augmentation of a sterilization dose established using Method 1, Method 2A or Method 2B 10.2.6.1 General 10.2.6.2 Stage 1: Analyse data from the failed sterilization dose audit <\/td>\n<\/tr>\n | ||||||
61<\/td>\n | 10.2.6.3 Stage 2: Determine extrapolation factor, E 10.2.6.4 Stage 3: Calculate adjusted dose (the dose to achieve an SAL value of 10\u20132) 10.2.6.5 Stage 4: Calculate augmented sterilization dose 10.3 Procedure for auditing a sterilization dose substantiated using Method VDmax25 or Method VDmax15 10.3.1 General <\/td>\n<\/tr>\n | ||||||
62<\/td>\n | 10.3.2 Stage 1: Obtain samples of product 10.3.3 Stage 2: Determine average bioburden 10.3.4 Stage 3: Perform verification dose experiment 10.3.5 Stage 4: Interpretation of results <\/td>\n<\/tr>\n | ||||||
63<\/td>\n | 10.3.6 Confirmatory sterilization dose audit 10.3.6.1 General 10.3.6.2 Stage 1: Obtain samples of product 10.3.6.3 Stage 2: Perform confirmatory verification dose experiment <\/td>\n<\/tr>\n | ||||||
64<\/td>\n | 10.3.6.4 Stage 3: Interpretation of results 10.3.7 Augmentation of a sterilization dose substantiated using Method VDmax25 or Method VDmax15 10.3.7.1 Method VDmax25 <\/td>\n<\/tr>\n | ||||||
65<\/td>\n | 10.3.7.2 Method VDmax15 <\/td>\n<\/tr>\n | ||||||
66<\/td>\n | 10.4 Failure of a sterilization dose audit 11 Worked examples 11.1 Worked examples for Method 1 <\/td>\n<\/tr>\n | ||||||
69<\/td>\n | 11.2 Worked examples for Method 2 11.2.1 General <\/td>\n<\/tr>\n | ||||||
70<\/td>\n | 11.2.2 Worked example for Method 2A (SIP equal to 1.0) 11.2.2.1 Stage 1: Select SAL and obtain samples of product 11.2.2.2 Stage 2: Perform incremental dose experiment <\/td>\n<\/tr>\n | ||||||
72<\/td>\n | Stage 3: Perform verification dose experiment <\/td>\n<\/tr>\n | ||||||
73<\/td>\n | 11.2.2.3 Stages 4 and 5: Interpretation of results and establishment of sterilization dose 11.2.3 Worked example for Method 2A (SIP less than 1.0) 11.2.3.1 Stage 1: Select SAL and obtain samples of product <\/td>\n<\/tr>\n | ||||||
74<\/td>\n | 11.2.3.2 Stage 2: Perform incremental dose experiment <\/td>\n<\/tr>\n | ||||||
76<\/td>\n | 11.2.3.3 Stage 3: Perform verification dose experiment <\/td>\n<\/tr>\n | ||||||
77<\/td>\n | 11.2.3.4 Stages 4 and 5: Interpretation of results and establishment of sterilization dose <\/td>\n<\/tr>\n | ||||||
78<\/td>\n | 11.2.4 Worked example for Method 2B 11.2.4.1 Stage 1: Select SAL and obtain samples of product 11.2.4.2 Stage 2: Perform incremental dose experiment <\/td>\n<\/tr>\n | ||||||
80<\/td>\n | 11.2.4.3 Stage 3: Perform verification dose experiment <\/td>\n<\/tr>\n | ||||||
81<\/td>\n | 11.2.4.4 Stages 4 and 5: Interpretation of results and establishment of sterilization dose 11.3 Worked examples for Method VDmax <\/td>\n<\/tr>\n | ||||||
83<\/td>\n | 11.4 Worked example of a sterilization dose audit for a dose established using Method 1, the findings from which necessitated augmentation of the sterilization dose <\/td>\n<\/tr>\n | ||||||
84<\/td>\n | 11.5 Worked example of a sterilization dose audit for a dose established using Method 2A, the findings from which necessitated augmentation of the sterilization dose <\/td>\n<\/tr>\n | ||||||
85<\/td>\n | 11.6 Worked example of a sterilization dose audit for a sterilization dose substantiated using Method VDmax25 <\/td>\n<\/tr>\n | ||||||
87<\/td>\n | Bibliography <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":" ANSI\/AAMI\/ ISO 11137-2: 2013\/(R)2019 – Sterilization of health care products-Radiation-Part 2: Establishing the sterilization dose<\/b><\/p>\n |